BACKGROUND AND PURPOSE: We assessed the effects of over-expressing the dual-specific phosphatase, mitogen-activated protein (MAP) kinase phosphatase-2 (MKP-2), in human umbilical vein endothelial cells (HUVECs) on inflammatory protein expression and apoptosis, two key features of endothelial dysfunction in disease. EXPERIMENTAL APPROACHES: We infected HUVECs for 40 h with an adenoviral version of MKP-2 (Adv.MKP-2). Tumour necrosis factor (TNF)-α-stimulated phosphorylation of MAP kinase and protein expression was measured by Western blotting. Cellular apoptosis was assayed by FACS. KEY RESULTS: Infection with Adv.MKP-2 selectively abolished TNF-α-mediated c-Jun-N-terminal kinase (JNK) activation and had little effect upon extracellular signal-regulated kinase or p38 MAP kinase. Adv.MKP-2 abolished COX-2 expression, while induction of the endothelial cell adhesion molecules, intercellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM), two NFκB-dependent proteins, was not affected. However, when ICAM and VCAM expression was partly reduced by blockade of the NFκB pathway, Adv.MKP-2 was able to reverse this inhibition. This correlated with enhanced TNF-α-induced loss of the inhibitor of κB (IκB)α loss, a marker of NFκB activation. TNF-α in combination with NFκB blockade also increased HUVEC apoptosis; this was significantly reversed by Adv.MKP-2. Protein markers of cellular damage and apoptosis, H2AX phosphorylation and caspase-3 cleavage, were also reversed by MKP-2 over-expression. CONCLUSIONS AND IMPLICATIONS: Over-expression of MKP-2 had different effects upon the expression of inflammatory proteins due to a reciprocal effect upon JNK and NFκB signalling, and also prevented TNF-α-mediated endothelial cell death. These properties may make Adv.MKP-2 a potentially useful future therapy in cardiovascular diseases where endothelial dysfunction is a feature.
BACKGROUND AND PURPOSE: We assessed the effects of over-expressing the dual-specific phosphatase, mitogen-activated protein (MAP) kinase phosphatase-2 (MKP-2), in human umbilical vein endothelial cells (HUVECs) on inflammatory protein expression and apoptosis, two key features of endothelial dysfunction in disease. EXPERIMENTAL APPROACHES: We infected HUVECs for 40 h with an adenoviral version of MKP-2 (Adv.MKP-2). Tumour necrosis factor (TNF)-α-stimulated phosphorylation of MAP kinase and protein expression was measured by Western blotting. Cellular apoptosis was assayed by FACS. KEY RESULTS: Infection with Adv.MKP-2 selectively abolished TNF-α-mediated c-Jun-N-terminal kinase (JNK) activation and had little effect upon extracellular signal-regulated kinase or p38 MAP kinase. Adv.MKP-2 abolished COX-2 expression, while induction of the endothelial cell adhesion molecules, intercellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM), two NFκB-dependent proteins, was not affected. However, when ICAM and VCAM expression was partly reduced by blockade of the NFκB pathway, Adv.MKP-2 was able to reverse this inhibition. This correlated with enhanced TNF-α-induced loss of the inhibitor of κB (IκB)α loss, a marker of NFκB activation. TNF-α in combination with NFκB blockade also increased HUVEC apoptosis; this was significantly reversed by Adv.MKP-2. Protein markers of cellular damage and apoptosis, H2AX phosphorylation and caspase-3 cleavage, were also reversed by MKP-2 over-expression. CONCLUSIONS AND IMPLICATIONS: Over-expression of MKP-2 had different effects upon the expression of inflammatory proteins due to a reciprocal effect upon JNK and NFκB signalling, and also prevented TNF-α-mediated endothelial cell death. These properties may make Adv.MKP-2 a potentially useful future therapy in cardiovascular diseases where endothelial dysfunction is a feature.
Authors: Soizic Daniel; Maria B Arvelo; Virendra I Patel; Christopher R Longo; Gautam Shrikhande; Tala Shukri; Jerome Mahiou; David W Sun; Christina Mottley; Shane T Grey; Christiane Ferran Journal: Blood Date: 2004-07-13 Impact factor: 22.113
Authors: Paolo Rosini; Giovanna De Chiara; Paolo Bonini; Maria Lucibello; Maria Elena Marcocci; Enrico Garaci; Federico Cozzolino; Maria Torcia Journal: J Biol Chem Date: 2004-01-14 Impact factor: 5.157
Authors: Raj Wadgaonkar; Jacqueline W Pierce; Kaumudi Somnay; Rachel L Damico; Michael T Crow; Tucker Collins; Joe G N Garcia Journal: Am J Respir Cell Mol Biol Date: 2004-07-01 Impact factor: 6.914
Authors: Felix C Tanner; Thomas Largiadèr; Helen Greutert; Zhihong Yang; Thomas F Lüscher Journal: J Thorac Cardiovasc Surg Date: 2004-01 Impact factor: 5.209
Authors: Alfredo Molina-Berríos; Carolina Campos-Estrada; Michel Lapier; Juan Duaso; Ulrike Kemmerling; Norbel Galanti; Jorge Ferreira; Antonio Morello; Rodrigo López-Muñoz; Juan Diego Maya Journal: Parasitol Res Date: 2013-05-17 Impact factor: 2.289
Authors: Derrick D Kao; Scott R Oldebeken; Anjali Rai; Edith Lubos; Jane A Leopold; Joseph Loscalzo; Diane E Handy Journal: Mol Cell Biochem Date: 2013-06-28 Impact factor: 3.396